	US 7,550,489 B2
	Substituted pyridyoxy amides
William K. Hagmann, Westfield, N.J. (US); Linus S. Lin, Westfield, N.J. (US); Shrenik K. Shah, Metuchen, N.J. (US); Ravindra N. Guthikonda, Edison, N.J. (US); Hongbo Qi, Edison, N.J. (US); Linda L. Chang, Wayne, N.J. (US); Ping Liu, Edison, N.J. (US); Helen M. Armstrong, Westfield, N.J. (US); James P. Jewell, Jersey City, N.J. (US); and Thomas J. Lanza, Jr., Edison, N.J. (US)
Assigned to Merck & Co., Inc., Rahway, N.J. (US)
Filed on Feb. 01, 2008, as Appl. No. 12/12,463.
Application 12/012463 is a division of application No. 11/109076, filed on Apr. 19, 2005.
Application 11/109076 is a division of application No. 10/387265, filed on Mar. 12, 2003, granted, now 6,972,295.
Claims priority of provisional application 60/428351, filed on Nov. 22, 2002.
Claims priority of provisional application 60/363597, filed on Mar. 12, 2002.
Prior Publication US 2008/0171692 A1, Jul. 17, 2008
Int. Cl. A61K 31/435 (2006.01)

U.S. Cl. 514—354 [514/355]

6 Claims

1. A composition comprising:

(A) a compound of structural formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R¹is selected from:

(1) aryl, and

(2) aryl-C_1-4alkyl,

wherein each alkyl is optionally substituted with one to four substituents independently selected from R^a, and each aryl is optionally substituted with one to four substituents independently selected from R^b;

R²is selected from:

(1) aryl, and

(2) aryl-C_1-4alkyl,

R³is selected from:

(1) hydrogen, and

(2) C_1-4alkyl,

wherein each alkyl is optionally substituted with one to four substituents independently selected from R^a;

R⁴is selected from:

(1) hydrogen, and

(2) C_1-4alkyl,

wherein each alkyl is optionally substituted with one to four substituents independently selected from R^a;

R⁵is selected from pyridyloxy and C_1-8alkyl substituted with pyridyloxy, wherein alkyl is optionally substituted with one to four substituents independently selected from R^a, and pyridyl is unsubstituted or substituted with one to three substituents independently selected from R^h;

each R^ais independently selected from:

(1) —OR^d,

(2) —NR^cS(O)_mR^d,

(3) halogen,

(4) —SR^d,

(5) —S(O)_mNR^cR^d,

(6) —NR^cR^d,

(7) —C(O)R^d,

(8) —CO₂R^d,

(9) —CN,

(10) —C(O)NR^cR^d,

(11) —NR^cC(O)R^d,

(12) —NR^cC(O)OR^d,

(13) —NR^cC(O)NR^cR^d,

(14) —CF₃, and

(15) —OCF₃;

each R^bis independently selected from:

(1) R^a,

(2) C_1-10alkyl,

(3) oxo,

(4) aryl, and

(5) arylC_1-4alkyl;

R^cand R^dare independently selected from:

(1) hydrogen,

(2) C_1-10alkyl,

(3) C_2-10alkenyl,

(4) cycloalkyl,

(5) cycloalkyl-C_1-10alkyl;

(6) aryl, and

(7) aryl-C_1-10alkyl,

each R^cand R^dmay be unsubstituted or substituted with one to three substituents selected from R^h;

each R^his independently selected from:

(1) halogen,

(2) C_1-10alkyl,

(3) —OC_1-4alkyl,

(4) —SC_1-4alkyl,

(5) —CN,

(6) —CF₃, and

(7) —OCF₃; and

m is selected from 1 and 2; and

(B) a second therapeutic agent selected from the group consisting of: an anorectic agents;

or a pharmaceutically acceptable salt thereof.